CardioMEMS HF System can be used as an option for remote monitoring of New York Heart Association (NYHA) class 3 chronic heart failure in adults at risk of hospitalisation who are:
able to use the technology (with the help of a carer if necessary) and
willing to adjust medication as directed.
More research is needed on the Cordella Pulmonary Artery Sensor System and the Cordella Heart Failure System for remote monitoring of NYHA class 3 chronic heart failure in adults before it can be funded by the NHS.
Can be used
There is enough evidence to show that CardioMEMS HF System provides benefits and value for money, so it should be used routinely across the NHS, and paid for using core NHS funding.
More research is needed
There is not enough evidence to support funding Cordella Pulmonary Artery Sensor System and the Cordella Heart Failure System in the NHS.
Access to Cordella Pulmonary Artery Sensor System and the Cordella Heart Failure System should be through company, research or non-core NHS funding, and clinical or financial risks should be managed appropriately.
More research is needed on:
the clinical effectiveness of the technology, including the impact on heart failure hospitalisations
the short-term impact of the technology on quality of life
defining which groups of people the technology is most suitable for.
Evidence from 3 randomised controlled trials shows that, when compared with usual care, CardioMEMS HF System (from here, CardioMEMS) can reduce heart failure hospitalisations in people with NYHA class 3 chronic heart failure who are at risk of hospitalisation. Evidence from non-comparative studies suggests that the Cordella Pulmonary Artery Sensor System and the Cordella Heart Failure System (from here, Cordella) may reduce heart failure hospitalisations, but this is unconfirmed. It is uncertain whether using either technology affects how long people live, or their quality of life. There are no trials directly comparing CardioMEMS with Cordella. An indirect comparison suggests no difference in heart failure hospitalisations between the 2 technologies. But this is uncertain because of the data used in the comparison.
Ongoing monitoring could be reassuring for people with chronic heart failure and help to quickly identify any need for medication changes. The technologies could reduce resource use in the NHS by reducing the number of heart failure hospitalisations. Use of the technology can be aided by carers as needed. People using the technology need to be willing to adjust medication as directed in order to benefit and reduce the risk of hospitalisation.
Evidence from economic modelling shows that CardioMEMS is likely to be cost effective. The cost effectiveness of Cordella cannot be established because its cost is unknown. Also, because there is limited evidence on its clinical effectiveness, Cordella can only be used in research.